Targeted agents for second-line treatment of advanced hepatocellular carcinoma

Table 5 Efficacy results of the REACH-2 phase III trial

Outcome	Ramucirumab n = 197 (%)	Placebo n = 95 (%)	HR (95%CI)	P value
Response
Complete	0	0	-	NR
Partial	9 (4.6)	1 (1.1)	-	NR
Overall response rate	9 (4.6)	1 (1.1)	-	0.1697
Stable disease	109 (55.3)	36 (37.9)	-	NR
Disease control rate	118 (59.9)	37 (38.9)	-	0.0006
Overall survival in mo			0.71 (0.53–0.94)	0.0199
Median	8.5	7.3
95%CI	7.0-10.6	5.4-9.1
Progression-free survival in mo			0.45 (0.33–0.60)	< 0.0001
Median	2.8	1.6
95%CI	2.8–4.1	1.5–2.7
Time to progression in mo			0.42 (0.31–0.58)	< 0.0001
Median	3.0	1.6
95%CI	(2.8–4.2)	(1.5–2.7)

Adapted from: Zhu et al[57]. CI: Confidence interval; NR: Not reported; HR: Hazard ratio.